It is worth noting that c-kit-associated inferior prognosis in AML1/ETO-positive AML patients is c-kit mutation-independent because the predictive capability of c-kit for both OS and EFS was further improved in the subgroup of patients carrying AML1/ETO and wtc-kit. This evidence concerns the gene RUNX1 and acute myeloid leukemia.